Cytodel Inc

From the company

of pageDelivering Therapeutic Proteins Via Neuronal Circuitry Intraneuronal Drug Delivery | Biobetter | Biodefense ABOUTCytoDel is a preclinical stage biopharmaceutical company developing recombinant botulinum toxin (rBoT) derivatives that can deliver therapeutics to the neuronal cytoplasmTECHNOLOGYCytoDel’s rBoT platform enables the creation of a new class of antibody fusion proteins, that specifically deliver their payload to previously inaccessible targets in the neuronal cytoplasmMore PROGRAMS Our lead program utilizes intraneuronal delivery for Biodefense, and additionally, CytoDel is developing programs for the treatment of nervous system disorders and chronic pain. A second program is a Biobetter BoT offering an improved safety margin and outcomes for the treatment of large muscles and muscle groups.More NEWS Publications Press Release: CytoDel Announces Pre-Clinical Data on.